Business Wire

Mobile Ticket Option Now Available for New York CityPASS Program

Jaa

New York City’s original big-savings ticket booklet now offers a mobile ticket option. The New York CityPASS® program, which saves travelers 40% off admission to the Big Apple’s very best attractions, including the Empire State Building, The Metropolitan Museum of Art and American Museum of Natural History, has gone mobile.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171128005460/en/

New York CityPASS mobile ticket. (Photo: Business Wire)

New York CityPASS mobile ticket. (Photo: Business Wire)

Offering packaged, discounted admission to the most iconic attractions in 12 North American destinations, City Pass, Inc. has always focused on making travel easier and less expensive. The company’s decision to offer mobile tickets—a move that dramatically enhances convenience for travelers—began last month with the successful launch of a similar option for the Tampa Bay CityPASS program.

“It was exciting to watch the debut of the New York mobile ticket option unfold in real time,” said CityPASS President and CEO Megan Allen. “Shortly after the option went live on our website, a pair of mobile tickets was purchased in Euros by a traveler who selected French as their language. Five minutes later, those same tickets were scanned for entry at one of our partner attractions.”

The language option is a benefit that will be applied to all future mobile ticket programs for other CityPASS partner destinations. Mobile tickets will be delivered to the purchaser’s smartphone in the language the buyer used while browsing the CityPASS website. For international visitors, it is especially helpful to have an end-to-end translated experience in the language of their choosing.

The New York CityPASS program includes prepaid admission to:

  • The Empire State Building (CityPASS day/night ticket includes two general admission visits: one during the day and a return visit the same night)
  • American Museum of Natural History
  • The Metropolitan Museum of Art
  • Option: Top of the Rock Observation Deck OR Guggenheim Museum
  • Option: Statue of Liberty & Ellis Island OR Circle Line Sightseeing Cruise
  • Option: 9/11 Memorial & Museum OR Intrepid Sea, Air & Space Museum

The included tickets are valid over a period of nine consecutive days, beginning with the first day of use.

The mobile ticket will work in the same manner as printed CityPASS ticket booklets, although instead of scanning a printed ticket at the attraction, the visitor will scan their phone. Mobile tickets, as well as ticket booklets, can be purchased online at CityPASS.com. Current prices (valid through Feb. 28, 2018): $122 for adults; $98 for children (6-17).

For 20 years, CityPASS ticket booklets and admission cards have been premier products for travelers who want to visit a destination’s top attractions while enjoying significant savings. CityPASS booklets/admission cards, which have a 98 percent customer recommendation rating, are available for New York City, Atlanta, Boston, Chicago, Dallas, Houston, Philadelphia, San Francisco, Seattle, Southern California, Tampa Bay and Toronto. For more information, visit CityPASS.com.

Prices and programs subject to change. CityPASS ® is a registered trademark of City Pass, Inc., and the exclusive property of City Pass, Inc.

Contact information

CityPASS
Deborah Wakefield, APR, 503-292-4418
deborah@citypass.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Customers of Palau Telecoms to Enjoy ‘Always On’ Connectivity with SES Networks19.2.2018 10:50Tiedote

Customers of Palau’s local internet services provider Palau Telecoms will continue to enjoy enhanced and reliable fibre-like connectivity delivered by SES Networks. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180218005047/en/ Customers of Palau Telecoms to Enjoy ‘Always On’ Connectivity with SES Networks (Photo: Business Wire) SES announced today that in the latest contract signed, Palau Telecoms, which has been enjoying SES’s Networks exceptional networks performance since 2014, will be extending its contract until 2020, and increasing the amount of medium earth orbit (MEO) connectivity by 150%. A long-term customer of SES Networks, Palau Telecoms is utilising their existing MEO service to augment fibre capacity, providing an ‘always on’ service to its customers. This enhanced, robust infrastructure provides a solid foundation for their 4G implementation plans, giving their end users the quality experience they demand reg

New data presented at the American Academy of Dermatology show LEO Pharma’s Kyntheum® (brodalumab) improves psoriasis on the nail19.2.2018 09:00Tiedote

NOT FOR DISTRIBUTION IN THE UNITED STATES OR UNITED KINGDOM: LEO Pharma today announced new data demonstrating long-term improvements in psoriasis on the nail with Kyntheum® (brodalumab) when compared to placebo or ustekinumab.1 Psoriasis on the nail, which is challenging to treat,2 affects approximately half of the estimated 125 million people living with psoriasis worldwide.2,3 The data were presented at the 76th annual American Academy of Dermatology (AAD) meeting in San Diego, California, US. Psoriasis is a common, chronic, immune-mediated, inflammatory disease that primarily involves the skin, but also impacts emotional, psychological and physical health.4 The heavy and far-reaching burden of the disease can be disabling and stigmatising with a substantial negative impact on those affected and their families.4 Due to the visible nature of the condition, psoriasis on the nail can be particularly upsetting for patients.4 In moderate to severe cases, psoriasis on the nail can be pain

OTEZLA® (Apremilast) Phase III Data Showed Significant Improvements in Patients with Active Behçet’s Disease with Oral Ulcers18.2.2018 00:00Tiedote

Celgene Corporation (NASDAQ:CELG) today announced that data from the phase III RELIEF™ clinical trial of OTEZLA® (apremilast) in patients with active Behçet’s Disease with oral ulcers were presented in a late-breaking oral presentation at the 2018 American Academy of Dermatology (AAD) Annual Meeting. The results showed statistically significant reductions in oral ulcers with apremilast 30 mg twice daily (BID) versus placebo through week 12. OTEZLA (apremilast) is Celgene’s oral selective inhibitor of phosphodiesterase 4 (PDE4). Behçet’s Disease is a rare, chronic, multi-system inflammatory syndrome. Oral ulcers, the most common manifestation of Behçet’s Disease, can be disabling and have a substantial effect on quality of life. This study primarily evaluated the effect of apremilast on recurring oral ulcers in patients with active Behçet’s Disease who were previously treated with at least one topical or systemic medication. “Reducing oral ulcers, which are painful and can negatively im

CT-P13 (biosimilar infliximab) is comparable to reference infliximab and adalimumab in highly anticipated real-world study17.2.2018 11:00Tiedote

Twelve-month data from the Personalised Anti-TNF therapy in Crohn’s disease Study (PANTS) was presented at the 13th Congress of the European Crohn’s and Colitis Organisation (ECCO). The results indicate that the clinical effectiveness, safety and immunogenicity of Celltrion Healthcare’s CT-P13 (biosimilar infliximab) in patients with Crohn’s disease (CD) is comparable to those treated with reference infliximab as well as those treated with adalimumab.1 The UK-wide, three-year prospective observational study investigated primary non-response (PNR), loss of response (LOR) and adverse drug reactions (ADR) to infliximab (reference infliximab and CT-P13) and adalimumab in 1610 CD patients. The data show comparable efficacy between CT-P13, reference infliximab and adalimumab in relation to PNR, LOR and ADR rates. In addition, at week 54, the remission rate was 39.7%, 39.0% and 32.7% for reference infliximab, CT-P13 and adalimumab treated patients, respectively.1 The PANTS study investigates

Avanti Communications HYLAS 4 Satellite Arrives in French Guiana16.2.2018 21:26Tiedote

Avanti Communications Group plc (“Avanti”), a leading provider of satellite data communications services in Europe, the Middle East and Africa (“EMEA”), announces its HYLAS 4 satellite has arrived safely in French Guiana ahead of its March 2018 launch. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180216005586/en/ Avanti Communications HYLAS 4 Satellite Arrives in French Guiana (Photo: Business Wire) The spacecraft, built by Orbital ATK was packed and shipped at their Satellite Manufacturing Facility in Dulles, Virginia, United States and flown to French Guiana, where it was unloaded and will be taken to the Arianespace launch facilities in Kourou. HYLAS 4 uses the latest High Throughput Satellite technology, doubling Avanti's Ka-band capacity across EMEA. The latest addition to Avanti's HYLAS fleet will provide: Backhaul services for mobile network operators Wholesale broadband for ISPs Connectivity for governments (civil a

General Cable Corporation Stockholders Approve Acquisition By Prysmian Group16.2.2018 20:05Tiedote

General Cable Corporation (NYSE: BGC) today announced the voting results from the Company’s special meeting of stockholders held this morning. Stockholders of General Cable approved the Company’s previously announced acquisition by Prysmian Group (BIT: PRY) for $30.00 per share in cash. A total of 38,140,754 shares, representing approximately 75.34% of the total number of shares of common stock outstanding and approximately 99% of the total votes cast, were voted in favor of the merger. Subject to regulatory approvals and other customary closing conditions, the transaction is expected to close by the third quarter of 2018. About General Cable General Cable (NYSE:BGC), with headquarters in Highland Heights, Kentucky, is a global leader in the development, design, manufacture, marketing and distribution of aluminum, copper and fiber optic wire and cable products for the energy, communications, automotive, industrial, construction and specialty segments. General Cable is one of the larges

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme